Zonisamide in the treatment of bulimia nervosa: An open-label, pilot, prospective study
Article first published online: 25 JUL 2013
Copyright © 2013 Wiley Periodicals, Inc.
International Journal of Eating Disorders
Volume 46, Issue 7, pages 747–750, November 2013
How to Cite
Guerdjikova, A. I., Blom, T. J., Martens, B. E., Keck, P. E. and McElroy, S. L. (2013), Zonisamide in the treatment of bulimia nervosa: An open-label, pilot, prospective study. Int. J. Eat. Disord., 46: 747–750. doi: 10.1002/eat.22159
- Issue published online: 28 OCT 2013
- Article first published online: 25 JUL 2013
- Manuscript Accepted: 4 JUN 2013
- Manuscript Revised: 15 MAY 2013
- Elan Pharmaceuticals Inc., San Diego, CA
- bulimia nervosa;
- eating disorder
To assess preliminarily the effectiveness of zonisamide in bulimia nervosa.
This was an open-label, prospective, 12-week, flexible dose study of zonisamide in bulimia nervosa. The primary outcome was binge-purge episode frequency.
Twelve individuals received zonisamide, 10 completed at least one post-baseline evaluation, and six completed the study. Mean dose at endpoint was 420 (SD = 215) mg/day. Zonisamide was associated with significant reductions in frequency of binge-purge episodes and binge-purge days as well as measures of binge eating behavior, purging behavior, clinical severity, obsessive-compulsive features, and depressive symptoms. Weight was unchanged.
In this open-label trial, zonisamide was effective in bulimia nervosa, but associated with a high discontinuation rate. © 2013 Wiley Periodicals, Inc. (Int J Eat Disord 2013; 46:747–750)